Teprotumumab (RV001, R1507) is a first-in-class IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular alpha-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research.
Purity:
99.0%
CAS Number:
[1036734-93-6]
Target:
IGF-1R
* VAT and and shipping costs not included. Errors and price changes excepted